Overview

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2015-04-30
Target enrollment:
Participant gender:
Summary
To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Pirfenidone